These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 3615554)

  • 1. [Polymorphism of drugs in powders and tablets. 6. X-ray diffractometric studies of polymorphic modifications of tolbutamide].
    Traue J; Kala H; Köhler M; Wenzel U; Förster B; Pollandt P; Pintye-Hódi K; Szabó-Révész P; Selmeczi B
    Pharmazie; 1987 Apr; 42(4):240-1. PubMed ID: 3615554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The polymorphism of drugs in powders and tablets. 5. Preparation and characterization of polymorphic forms of tolbutamide].
    Traue J; Kala H; Köhler M; Wenzel U; Wiegeleben A; Pintye-Hódi K; Szabó-Révész P; Selmeczi B
    Pharmazie; 1987 Mar; 42(3):181-3. PubMed ID: 3602075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The polymorphism of drugs in powders and tablets. 2. X-ray diffraction studies of polymorphic modifications of phenobarbital].
    Traue J; Kala H; Wenzel U; Förster B; Pintyehódi K; Szabó P; Miseta M; Selmeczi B; Kedvessy G
    Pharmazie; 1986 Apr; 41(4):291-2. PubMed ID: 3725878
    [No Abstract]   [Full Text] [Related]  

  • 4. Crystallization and X-ray diffraction of spray-dried and freeze-dried amorphous lactose.
    Haque MK; Roos YH
    Carbohydr Res; 2005 Feb; 340(2):293-301. PubMed ID: 15639249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [On the polymorphism of barbiturates in powders and tablets - Part 3: The effect of the pressing power on the modification of barbital (author's transl)].
    Pintye-Hódi K; Hollenbach K
    Pharmazie; 1979 Dec; 34(12):807-8. PubMed ID: 545349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The polymorphism of drugs in powders and tablets. 1. The preparation and characterization of polymorphic modifications of phenobarbital].
    Traue J; Kala H; Wenzel U; Wiegeleben A; Pintye-Hódi K; Szabó-Révész P; Miseta M; Selmeczi B; Kedvessy G
    Pharmazie; 1987 Feb; 42(2):86-9. PubMed ID: 3602065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Qualitative and quantitative analysis of clopidogrel bisulphate polymorphs.
    Koradia V; Chawla G; Bansal AK
    Acta Pharm; 2004 Sep; 54(3):193-204. PubMed ID: 15610616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative analysis of crystalline pharmaceuticals in tablets by pattern-fitting procedure using X-ray diffraction pattern.
    Takehira R; Momose Y; Yamamura S
    Int J Pharm; 2010 Oct; 398(1-2):33-8. PubMed ID: 20674727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative determination of famotidine polymorphs: X-ray powder diffractometric and Raman spectrometric study.
    Német Z; Kis GC; Pokol G; Demeter A
    J Pharm Biomed Anal; 2009 Feb; 49(2):338-46. PubMed ID: 19131203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal morphologies and polymorphs in tolbutamide microcrystalline powder.
    Li Destri G; Marrazzo A; Rescifina A; Punzo F
    J Pharm Sci; 2013 Jan; 102(1):73-83. PubMed ID: 23042550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of crystallinity on the rate of solution of oxytetracycline hydrochloride].
    Grakovskaia LK; Nesterova LIa
    Antibiotiki; 1982 Nov; 27(11):815-20. PubMed ID: 7181463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystal forms of tolbutamide from acetonitrile and 1-octanol: effect of solvent, humidity and compression pressure.
    Chakravarty P; Alexander KS; Riga AT; Chatterjee K
    Int J Pharm; 2005 Jan; 288(2):335-48. PubMed ID: 15620874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of Henderson equation for the determination of weakly acidic pharmaceutical compounds. Part 2. Determination of tolbutamide.
    El-Fatatry HM; Sharaf El-Deen MM; Amer MM
    Pharmazie; 1979; 34(9):543-5. PubMed ID: 542486
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of spray-dried co-precipitate of amorphous celecoxib containing storage and compression stabilizers.
    Dhumal RS; Shimpi SL; Paradkar AR
    Acta Pharm; 2007 Sep; 57(3):287-300. PubMed ID: 17878109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solid-state characterization of two polymorphic forms of R-albuterol sulfate.
    Palacio MA; Cuffini S; Badini R; Karlsson A; Palacios SM
    J Pharm Biomed Anal; 2007 Mar; 43(4):1531-4. PubMed ID: 17141446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aerosolization properties, surface composition and physical state of spray-dried protein powders.
    Bosquillon C; Rouxhet PG; Ahimou F; Simon D; Culot C; Préat V; Vanbever R
    J Control Release; 2004 Oct; 99(3):357-67. PubMed ID: 15451594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advantages of celecoxib nanosuspension formulation and transformation into tablets.
    Dolenc A; Kristl J; Baumgartner S; Planinsek O
    Int J Pharm; 2009 Jul; 376(1-2):204-12. PubMed ID: 19426794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The usefulness of simple X-ray powder diffraction analysis for counterfeit control--the Viagra example.
    Maurin JK; Pluciński F; Mazurek AP; Fijałek Z
    J Pharm Biomed Anal; 2007 Mar; 43(4):1514-8. PubMed ID: 17127026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Floating hot-melt extruded tablets for gastroretentive controlled drug release system.
    Fukuda M; Peppas NA; McGinity JW
    J Control Release; 2006 Oct; 115(2):121-9. PubMed ID: 16959356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nano- and macro-geometrical structural change of caffeine and theophylline anhydrate tablets during hydration process by using X-ray computed tomography.
    Otsuka M; Ibe K; Tokudome Y; Ohshima H
    Colloids Surf B Biointerfaces; 2009 Oct; 73(2):351-9. PubMed ID: 19559580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.